Methods for the treatment of cancer

• US 8,008,281 B2
• Filed: 02/20/2004
• Issued: 08/30/2011
• Est. Priority Date: 03/27/2003
• Status: Active Grant

• Current Assignee: Lankenau Institute for Medical Research
• Original Assignee: Lankenau Institute for Medical Research
• Inventors: Muller, Alexander J., Malachowski, William, Prendergast, George C., DuHadaway, James B.
• Primary Examiner(s): Fetterolf; Brandon
• Assistant Examiner(s): Stone; Christopher R
• Application Number:
  US10/551,151
• Publication Number:
  US 20070099844A1
• Time in Patent Office: 2,748 Days
• Field of Search: 514/183
• US Class Current: 514/183
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 38/04 Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof enzyme inhibitors A61K38/005; gastrins A61K38/2207, somatostatins A61K38/31, melanotropins A61K38/34 ; protease inhibitors A61K38/55
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 209/14 Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• CPC Class Codes: C07D 403/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 513/04 Ortho-condensed systems
• CPC Class Codes: C07D 517/04 Ortho-condensed systems

Abstract

Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.

Claims

1. A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is methyl-TH-DL-trp.

2. The method of claim 1, wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel, cisplatin, docetaxel, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epbthilone derivatives.

3. The method of claim 2, wherein said at least one chemotherapeutic agent is paclitaxel.

4. The method of claim 1, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered concurrently.

5. The method of claim 1, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered sequentially.

6. The method of claim 5, wherein said at least one IDO inhibitor is administered before said at least one chemotherapeutic agent.

7. The method of claim 5, wherein said at least one chemotherapeutic agent is administered before said at least one IDO inhibitor.

8. The method of claim 1, wherein said cancer is selected from the group consisting of cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone;

melanoma, basal carcinoma, lymphoma, leukemia, small-cell lung carcinoma, non-small-cell lung carcinoma, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.

9. The method of claim 8, wherein said cancer is selected from the group consisting of ovarian cancer, leukemia, melanoma, breast cancer, colorectal cancer, and lung cancer.

10. The method of claim 9, wherein said cancer is breast cancer.

11. A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is 1-methyl-DL-tryptophan, wherein said cancer is breast cancer, and wherein said chemotherapeutic agent is cisplatin.

12. The method of claim 11, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered concurrently.

13. The method of claim 11, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered sequentially.

14. The method of claim 13, wherein said at least one IDO inhibitor is administered before said at least one chemotherapeutic agent.

15. The method of claim 13, wherein said at least one chemotherapeutic agent is administered before said at least one IDO inhibitor.